Phase III Data Put Zealand's Dasiglucagon On Track, But Behind Others, For Hypoglycemia Rescue
Zealand Pharma stresses fast onset of dasiglucagon, which it plans to file on its own but develop commercially through partnership.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Early results confirm dasiglucagon's safety profile with no treatment-induced or treatment-boosted anti-drug antibodies.
Eli Lilly & Co has acquired the worldwide rights to Locemia Solutions' Phase III intranasal glucagon product for the treatment of severe hypoglycemia – which it hopes will be the first needle-free option to gain approval for this indication.